Daniel Apel Biography and Net Worth

Chief Financial Officer of Arrowhead Pharmaceuticals

Dan Apel brings over 25 years of US and global financial experience to Arrowhead. Prior to joining Arrowhead he served as Global Head of Financial Planning and Analysis from 2019 through 2024 at Walgreens Boots Alliance WBA. Mr. Apel also served in various capacities in his nearly 20-year career at Bayer, including as Chief Financial Officer for Bayer U.S. from 2016 through 2019, as Chief Financial Officer for Bayer Canada and as global Head of Accounting for the Bayer Healthcare Segment, based in Germany. He served on the boards of the Biotechnology Innovation Organization (BIO) and the Organization for International Investment, as well as a Trustee for the Health Institute of New Jersey.

Mr. Apel earned his Master’s degree in Business Administration from the University of California, Berkeley, a Bachelors of Arts Degree from the University of Pennsylvania, and is a licensed Certified Public Accountant.

What is Daniel Joseph Apel's net worth?: The estimated net worth of Daniel Joseph Apel is at least $12.04 million as of April 22nd, 2026. Mr. Apel owns 162,905 shares of Arrowhead Pharmaceuticals stock worth more than $12,040,309 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Apel may own. Learn More about Daniel Joseph Apel's net worth.
How do I contact Daniel Joseph Apel?: The corporate mailing address for Mr. Apel and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Daniel Joseph Apel's contact information.
Has Daniel Joseph Apel been buying or selling shares of Arrowhead Pharmaceuticals?: During the last quarter, Daniel Joseph Apel has sold $934,328.25 in shares of Arrowhead Pharmaceuticals stock. Most recently, Daniel Joseph Apel sold 13,095 shares of the business's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a transaction totalling $934,328.25. Following the completion of the sale, the chief financial officer now directly owns 162,905 shares of the company's stock, valued at $11,623,271.75. Learn More on Daniel Joseph Apel's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Daniel Apel (Chief Financial Officer), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Hongbo Lu (Director), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Michael Perry (Director), Javier San Martin (Insider), Victoria Vakiener (Director), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, insiders at the biotechnology company sold shares 23 times. They sold a total of 603,931 shares worth more than $37,654,288.73. The most recent insider tranaction occured on April, 23rd when insider James C Hamilton sold 10,000 shares worth more than $750,000.00. Insiders at Arrowhead Pharmaceuticals own 3.6% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 4/23/2026.

Daniel Joseph Apel Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/22/2026	Sell	13,095	$71.35	$934,328.25	162,905

Daniel Joseph Apel Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $73.91

$73.26

$75.32

50 Day Range

MA: $62.83

$55.01

$74.40

2 Week Range

Now: $73.91

$12.44

$76.76

Volume

1,639,041 shs

Average Volume

1,772,713 shs

Market Capitalization

$10.35 billion

P/E Ratio

48.31

Dividend Yield

N/A

Beta

1.26